

**Opportunity Title:** FDA Postdoctoral Research Opportunity in Microbiology

**Opportunity Reference Code:** FDA-CBER-2020-0013



**Organization** U.S. Food and Drug Administration (FDA)

**Reference Code** FDA-CBER-2020-0013

**How to Apply**

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation. Your application will be considered incomplete, and will not be reviewed until one recommendation is submitted.

All documents must be in English or include an official English translation.

If you have questions, send an email to [ORISE.FDA.CBER@orau.org](mailto:ORISE.FDA.CBER@orau.org). Please include the reference code for this opportunity in your email.

**Application Deadline** 2/28/2021 3:00:00 PM Eastern Time Zone

**Description**

**\*Applications will be reviewed on a rolling-basis.**

A research opportunity is currently available in the laboratory of Dr. Paul Carlson, in the Office of Vaccines Research and Reviews (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Under the guidance of a mentor, the selected participant will be involved in projects designed to assess the potential of bacteriophage therapies against Vancomycin resistant Enterococcus species.

Since the advent of antibiotics in the 1920s, these drugs have saved millions of people from diseases such as pneumonias, healthcare associated infections, and foodborne illnesses. However, the continued use of antibiotics has led to several unintended consequences, including disruption of the indigenous beneficial gut bacteria and a rise in antibiotic-resistant bacteria. The Centers for Disease Control and Prevention (CDC) estimates that 23,000 deaths are caused by antibiotic-resistant bacteria each year in the United States, and these organisms constitute a growing problem worldwide. Vancomycin-resistant enterococci (VRE), which have been classified as a serious threat by the CDC, are responsible for 20,000 U.S. infections annually. The inability to treat these infections with common antibiotics necessitates the development of alternative methods of intervention. The objective of this project is to develop and characterize an effective bacteriophage therapy against VRE, including both vancomycin-resistant *E. faecalis* and *E. faecium*. The project will include mouse model development as well as assessment of bacteriophage efficacy and pharmacokinetics in this model system. Additional studies will determine mutations that result in bacterial resistance against bacteriophage and understanding how to overcome this resistance to generate a successful therapeutic. These bacteriophage therapy investigations will have a significant impact on a largely understudied field and contribute to solving the antibiotic-resistant bacteria problem. The participant will be involved with all aspects of this project, learning basic microbiology, bacteriophage biology, use of animal models for VRE and phage therapy evaluation, and various bioinformatic tools.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

**Opportunity Title:** FDA Postdoctoral Research Opportunity in Microbiology

**Opportunity Reference Code:** FDA-CBER-2020-0013

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.




### Qualifications

The qualified candidate should have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.

Preferred skills:

- Strong experience in microbiology and animal models of disease
- Excellent written and oral communication skills in English
- Experience in bioinformatics

### Eligibility Requirements

- **Citizenship:** U.S. Citizen Only
- **Degree:** Doctoral Degree received within the last 60 months or anticipated to be received by 10/1/2020 11:59:00 PM.
- **Discipline(s):**
  - **Engineering** (2 )
  - **Environmental and Marine Sciences** (1 )
  - **Life Health and Medical Sciences** (45 )